Literature DB >> 23063430

Failure of implantable cardioverter-defibrillator leads: a matter of lead size?

Roberto Rordorf1, Luca Poggio, Simone Savastano, Alessandro Vicentini, Barbara Petracci, Enrico Chieffo, Catherine Klersy, Maurizio Landolina.   

Abstract

BACKGROUND: Small-diameter implantable cardioverter-defibrillator (ICD) Sprint Fidelis and Riata leads have been recalled owing to an increased risk of lead failure, thus arousing the suspicion that lead size might be a critical issue.
OBJECTIVE: To compare the incidence of failure of small-diameter (≤8 F) and standard-diameter (>8 F) ICD leads implanted in a single center.
METHODS: From January 2003 to December 2010, 190 Sprint Fidelis, 182 Riata/Riata ST, 99 Optim (Riata Optim/Durata), and 419 standard-diameter leads were implanted in our center.
RESULTS: During a median follow-up of 33 months, the overall failure rate was 6.3%. Follow-up duration was similar for Sprint Fidelis, Riata, and standard-diameter leads but shorter for the Optim group. The failure rate was significantly higher in Sprint Fidelis leads than in both standard-diameter (4.8%/year vs 0.8%/year; P<.001) and Riata/Riata ST (4.8%/year vs 2.6%/year; P = .03) leads. The incidence of lead failure in Riata/Riata ST leads proved significantly higher than in standard-diameter leads (2.6%/year vs 0.8%/year; P = .001). No cases of lead failure were recorded in the Optim group. On multivariable analyses, small-diameter (hazard ratio [HR] 5.03, 2.53-10.01, P<.001), Sprint Fidelis (HR 6.3, 3.1-13.3, P<.001), or Riata/Riata ST (HR 4.5, 1.9-10.5, P = .001) leads and age<60 years (HR 2.3, 1.3-4.3, P = .005) were found to independently increase the risk of lead failure.
CONCLUSIONS: Compared with standard-diameter leads, both Sprint Fidelis and Riata/Riata ST small-diameter ICD leads are at an increased risk of failure, although the incidence of events is significantly lower in the Riata than in the Sprint Fidelis group.
Copyright © 2013 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23063430     DOI: 10.1016/j.hrthm.2012.10.017

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  7 in total

1.  Longitudinal follow-up of Riata leads reveals high annual incidence of new conductor externalization and electrical failure.

Authors:  Christian Steinberg; Jean-François Sarrazin; François Philippon; Jean Champagne; Marc-André Bouchard; Franck Molin; Isabelle Nault; Louis Blier; Gilles O'Hara
Journal:  J Interv Card Electrophysiol       Date:  2014-11-16       Impact factor: 1.900

2.  Axillary vein puncture using fluoroscopic landmarks: a safe and effective approach for implantable cardioverter defibrillator leads.

Authors:  Federico Migliore; Mariachiara Siciliano; Manuel De Lazzari; Sonia Ferretto; Chiara Dalla Valle; Alessandro Zorzi; Domenico Corrado; Sabino Iliceto; Emanuele Bertaglia
Journal:  J Interv Card Electrophysiol       Date:  2015-05-09       Impact factor: 1.900

3.  Riata type implantable cardiac defibrillator leads: increasingly small, progressively troublesome.

Authors:  A Elvan; A Adiyaman
Journal:  Neth Heart J       Date:  2013-03       Impact factor: 2.380

4.  First time description of early lead failure of the Linox Smart lead compared to other contemporary high-voltage leads.

Authors:  Vanessa Weberndörfer; Tobias Nyffenegger; Ian Russi; Miriam Brinkert; Benjamin Berte; Stefan Toggweiler; Richard Kobza
Journal:  J Interv Card Electrophysiol       Date:  2018-05-01       Impact factor: 1.900

Review 5.  Transvenous Implantable Cardioverter-Defibrillator (ICD) Lead Performance: A Meta-Analysis of Observational Studies.

Authors:  Rui Providência; Daniel B Kramer; Dominic Pimenta; Girish G Babu; Laura A Hatfield; Adam Ioannou; Jan Novak; Robert G Hauser; Pier D Lambiase
Journal:  J Am Heart Assoc       Date:  2015-10-30       Impact factor: 5.501

6.  Prospective long-term follow-up of silicone-polyurethane-insulated implantable cardioverter-defibrillator leads.

Authors:  John A Cairns; Jeff S Healey; Andrew E Epstein; Ellison Themeles; Kumar Balasubramanian; Stuart J Connolly
Journal:  Heart Rhythm O2       Date:  2021-12-01

7.  Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA.

Authors:  Ken O'Day; Wayne C Levy; Meridith Johnson; Arnold F Jacobson
Journal:  Appl Health Econ Health Policy       Date:  2016-06       Impact factor: 2.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.